Trials / Terminated
TerminatedNCT02278783
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | regorafenib | Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-07-01
- Completion
- 2017-01-01
- First posted
- 2014-10-30
- Last updated
- 2017-10-06
- Results posted
- 2016-12-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02278783. Inclusion in this directory is not an endorsement.